Studio di follow-up naturalistico sull'impiego dei Sali di Litio, in monoterapia o in associazione ad altri stabilizzatori dell'umore, nel trattamento del Disturbo Bipolare.

Data la natura cronica e ricorrente del Disturbo Bipolare è necessario instaurare un trattamento farmacologico profilattico a lungo termine. I Sali di Litio rappresentano ancora oggi il gold-standard per la prevenzione delle recidive, soprattutto maniacali, e possiedono una ben documentata azione antisuicidaria. Tuttavia, a causa dello stretto indice terapeutico il Litio necessita di un attento monitoraggio dei suoi livelli ematici, per ottimizzare l’efficacia del trattamento e prevenirne la tossicità. Obiettivo del nostro studio di follow-up naturalistico è stato quello di monitorare i pazienti con Disturbo Bipolare in trattamento di mantenimento con Sali di Litio afferenti presso il Day Hospital della Clinica Psichiatrica dell’Università di Pisa; ci siamo inoltre proposti di valutare il rapporto tra valori di litiemia e decorso clinico del disturbo e i possibili vantaggi dell'associazione del litio ad altri stabilizzatori dell’umore. Sono stati reclutati 98 pazienti con diagnosi di DB I o II secondo i criteri del DSM-IV-TR, dei quali 36 erano in trattamento con solo Litio e 62 con Litio associato ad un altro stabilizzatori dell’umore. Le valutazioni diagnostiche e sintomatologiche hanno previsto l’utilizzo della SCID-I e della CGI. La litiemia media del campione è risultata di 0.49 mEq/L±0.20, con valori superiori nel gruppo di pazienti con litio associato ad un altro stabilizzante rispetto al gruppo con solo litio e nei pazienti con episodio in atto rispetto ai pazienti eutimici; tuttavia, i pazienti con episodio depressivo hanno presentato valori di litiemia più bassi dei pazienti in fase maniacale o mista. Inoltre, livelli superiori di litiemia sono stati riscontrati nei soggetti con una maggiore gravità sul piano longitudinale del disturbo, caratterizzato prevalentemente da fasi espansive e rapida ciclicità. Dai nostri dati è emerso come i soggetti con valori di litiemia media nel range terapeutico siano andati incontro ad un miglioramento clinico in percentuale significativamente superiore rispetto ai soggetti con litiemia media inferiore; questo miglioramento è stato evidenziato sia per i pazienti con episodio in atto maniacale o misto che depressivo. Infine abbiamo osservato come l’associazione di un secondo stabilizzante (valproato o carbamazepina) al litio produca un miglioramento significativamente superiore della sintomatologia maniacale o mista e dell'impulsività rispetto al solo litio

A new look at an old drug: Neuroprotective effects and therapeutic potentials of lithium salts

Increasing evidence highlights bipolar disorder as being associated with impaired neurogenesis, cellular plasticity, and resiliency, as well as with cell atrophy or loss in specific brain regions. This has led most recent research to focus on the possible neuroprotective effects of medications, and particularly interesting findings have emerged for lithium. A growing body of evidence from preclinical in vitro and in vivo studies has in fact documented its neuroprotective effects from different insults acting on cellular signaling pathways, both preventing apoptosis and increasing neurotrophins and cell-survival molecules. Furthermore, positive effects of lithium on neurogenesis, brain remodeling, angiogenesis, mesenchymal stem cells functioning, and inflammation have been revealed, with a key role played through the inhibition of the glycogen synthase kinase-3, a serine/threonine kinase implicated in the pathogenesis of many neuropsychiatric disorders. These recent evidences suggest the potential utility of lithium in the treatment of neurodegenerative diseases, neurodevelopmental disorders, and hypoxic-ischemic/traumatic brain injury, with positive results at even lower lithium doses than those traditionally considered to be antimanic. The aim of this review is to briefly summarize the potential benefits of lithium salts on neuroprotection and neuroregeneration, emphasizing preclinical and clinical evidence suggesting new therapeutic potentials of this drug beyond its mood stabilizing properties

Aves en los cancioneros : zoohistoria, simbología y funcionalidad del papagayo en la lírica peninsular entre los siglos XIII y XV

The Galician-Portuguese lyrical poetry contains very few references of animals. In the case of birds, for example, they are just mentioned there, without any specification. One of the few exceptions is a pastorela poem (B534, V137) by King Denis of Portugal (r. 1279-1325), where a parrot talks about love with a young shepherdess. Parrots, poets and nightingales interact in texts of the fourteenth and early fifteenth century, as the Libro de Buen Amor, Celestina, the Poem of Alfonso XI, and in love or satirical poems of some antiquiores and recentiores poets of the Cancionero de Baena (PN1), or the Cancionero de Palacio (SA7), such as the Marquis de Santillana. This article seeks to follow the possible zoohistorical and literary appearances of the parrot (not macaw parrot), beginning with its description in bestiaries, its mention in the Digenis Akritas, in the Occitan roman Novas del Papagai, the Sendebar or La doncella Theodor, and also in some iconography, trying to shed light on its symbolism and function as a messenger of love in Peninsular lyrical poetry. La lírica profana gallego-portuguesa resulta un corpus pobre en referencias animales. En el caso de las aves, por lo general estas apenas son nombradas allí sin especificación. Una de las pocas excepciones la constituye una cantiga con motivo de pastorela (B534, V137) del rey Don Denis de Portugal (r. 1279-1325) donde un papagayo dialoga amorosamente con una joven pastora. Gayos, poetas y ruiseñores interactúan en textos del siglo XIV y principios del XV, como el Libro de Buen Amor, la Celestina, el Poema de Alfonso XI, y en piezas de tono amoroso o satírico de algunos poetas antiquiores y recentiores del Cancionero de Baena (PN1), o del Cancionero de Palacio (SA7), como el Marqués de Santillana. Buscaremos en este trabajo seguir el posible recorrido zoohistórico y literario del papagayo (loro y no guacamayo) desde, por ejemplo, su descripción en bestiarios, su mención en el Digenis Akritas, en el roman de las Novas del papagai y textos líricos occitanos, el Sendebar o la historia de La doncella Theodor, así como en cierta iconografía, intentando arrojar luz sobre su simbología y funcionalidad en tanto ave portadora de un mensaje amoroso cortés en la lírica peninsular

Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey

Background: There is mounting evidence on the existence of a Pediatric Inflammatory Multisystem Syndrome-temporally associated to SARS-CoV-2 infection (PIMS-TS), sharing similarities with Kawasaki Disease (KD). The main outcome of the study were to better characterize the clinical features and the treatment response of PIMS-TS and to explore its relationship with KD determining whether KD and PIMS are two distinct entities. Methods: The Rheumatology Study Group of the Italian Pediatric Society launched a survey to enroll patients diagnosed with KD (Kawasaki Disease Group - KDG) or KD-like (Kawacovid Group - KCG) disease between February 1st 2020, and May 31st 2020. Demographic, clinical, laboratory data, treatment information, and patients' outcome were collected in an online anonymized database (RedCAP®). Relationship between clinical presentation and SARS-CoV-2 infection was also taken into account. Moreover, clinical characteristics of KDG during SARS-CoV-2 epidemic (KDG-CoV2) were compared to Kawasaki Disease patients (KDG-Historical) seen in three different Italian tertiary pediatric hospitals (Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste; AOU Meyer, Florence; IRCCS Istituto Giannina Gaslini, Genoa) from January 1st 2000 to December 31st 2019. Chi square test or exact Fisher test and non-parametric Wilcoxon Mann-Whitney test were used to study differences between two groups. Results: One-hundred-forty-nine cases were enrolled, (96 KDG and 53 KCG). KCG children were significantly older and presented more frequently from gastrointestinal and respiratory involvement. Cardiac involvement was more common in KCG, with 60,4% of patients with myocarditis. 37,8% of patients among KCG presented hypotension/non-cardiogenic shock. Coronary artery abnormalities (CAA) were more common in the KDG. The risk of ICU admission were higher in KCG. Lymphopenia, higher CRP levels, elevated ferritin and troponin-T characterized KCG. KDG received more frequently immunoglobulins (IVIG) and acetylsalicylic acid (ASA) (81,3% vs 66%; p = 0.04 and 71,9% vs 43,4%; p = 0.001 respectively) as KCG more often received glucocorticoids (56,6% vs 14,6%; p < 0.0001). SARS-CoV-2 assay more often resulted positive in KCG than in KDG (75,5% vs 20%; p < 0.0001). Short-term follow data showed minor complications. Comparing KDG with a KD-Historical Italian cohort (598 patients), no statistical difference was found in terms of clinical manifestations and laboratory data. Conclusion: Our study suggests that SARS-CoV-2 infection might determine two distinct inflammatory diseases in children: KD and PIMS-TS. Older age at onset and clinical peculiarities like the occurrence of myocarditis characterize this multi-inflammatory syndrome. Our patients had an optimal response to treatments and a good outcome, with few complications and no deaths

Colorectal Cancer Stage at Diagnosis Before vs During the COVID-19 Pandemic in Italy

IMPORTANCE Delays in screening programs and the reluctance of patients to seek medical attention because of the outbreak of SARS-CoV-2 could be associated with the risk of more advanced colorectal cancers at diagnosis. OBJECTIVE To evaluate whether the SARS-CoV-2 pandemic was associated with more advanced oncologic stage and change in clinical presentation for patients with colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS This retrospective, multicenter cohort study included all 17 938 adult patients who underwent surgery for colorectal cancer from March 1, 2020, to December 31, 2021 (pandemic period), and from January 1, 2018, to February 29, 2020 (prepandemic period), in 81 participating centers in Italy, including tertiary centers and community hospitals. Follow-up was 30 days from surgery. EXPOSURES Any type of surgical procedure for colorectal cancer, including explorative surgery, palliative procedures, and atypical or segmental resections. MAIN OUTCOMES AND MEASURES The primary outcome was advanced stage of colorectal cancer at diagnosis. Secondary outcomes were distant metastasis, T4 stage, aggressive biology (defined as cancer with at least 1 of the following characteristics: signet ring cells, mucinous tumor, budding, lymphovascular invasion, perineural invasion, and lymphangitis), stenotic lesion, emergency surgery, and palliative surgery. The independent association between the pandemic period and the outcomes was assessed using multivariate random-effects logistic regression, with hospital as the cluster variable. RESULTS A total of 17 938 patients (10 007 men [55.8%]; mean [SD] age, 70.6 [12.2] years) underwent surgery for colorectal cancer: 7796 (43.5%) during the pandemic period and 10 142 (56.5%) during the prepandemic period. Logistic regression indicated that the pandemic period was significantly associated with an increased rate of advanced-stage colorectal cancer (odds ratio [OR], 1.07; 95%CI, 1.01-1.13; P = .03), aggressive biology (OR, 1.32; 95%CI, 1.15-1.53; P < .001), and stenotic lesions (OR, 1.15; 95%CI, 1.01-1.31; P = .03). CONCLUSIONS AND RELEVANCE This cohort study suggests a significant association between the SARS-CoV-2 pandemic and the risk of a more advanced oncologic stage at diagnosis among patients undergoing surgery for colorectal cancer and might indicate a potential reduction of survival for these patients

Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

Funder: Funder: Fundación bancaria ‘La Caixa’ Number: LCF/PR/PR16/51110003 Funder: Grifols SA Number: LCF/PR/PR16/51110003 Funder: European Union/EFPIA Innovative Medicines Initiative Joint Number: 115975 Funder: JPco-fuND FP-829-029 Number: 733051061Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease

Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study

Objectives. Racial factors play a significant role in SSc. We evaluated differences in SSc presentations between white patients (WP), Asian patients (AP) and black patients (BP) and analysed the effects of geographical locations.Methods. SSc characteristics of patients from the EUSTAR cohort were cross-sectionally compared across racial groups using survival and multiple logistic regression analyses.Results. The study included 9162 WP, 341 AP and 181 BP. AP developed the first non-RP feature faster than WP but slower than BP. AP were less frequently anti-centromere (ACA; odds ratio (OR) = 0.4, P < 0.001) and more frequently anti-topoisomerase-I autoantibodies (ATA) positive (OR = 1.2, P = 0.068), while BP were less likely to be ACA and ATA positive than were WP [OR(ACA) = 0.3, P < 0.001; OR(ATA) = 0.5, P = 0.020]. AP had less often (OR = 0.7, P = 0.06) and BP more often (OR = 2.7, P < 0.001) diffuse skin involvement than had WP.AP and BP were more likely to have pulmonary hypertension [OR(AP) = 2.6, P < 0.001; OR(BP) = 2.7, P = 0.03 vs WP] and a reduced forced vital capacity [OR(AP) = 2.5, P < 0.001; OR(BP) = 2.4, P < 0.004] than were WP. AP more often had an impaired diffusing capacity of the lung than had BP and WP [OR(AP vs BP) = 1.9, P = 0.038; OR(AP vs WP) = 2.4, P < 0.001]. After RP onset, AP and BP had a higher hazard to die than had WP [hazard ratio (HR) (AP) = 1.6, P = 0.011; HR(BP) = 2.1, P < 0.001].Conclusion. Compared with WP, and mostly independent of geographical location, AP have a faster and earlier disease onset with high prevalences of ATA, pulmonary hypertension and forced vital capacity impairment and higher mortality. BP had the fastest disease onset, a high prevalence of diffuse skin involvement and nominally the highest mortality

New insights into the genetic etiology of Alzheimer's disease and related dementias

Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele